Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
FDA Approvals
FDA Approvals
,
Select Drug Profiles
Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma
Read More
Drug Updates
,
FDA Approvals
,
Prostate Cancer
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer
Read More
Drug Updates
,
FDA Approvals
Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer
Read More
Drug Updates
,
FDA Approvals
Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation
Read More
Breast Cancer
,
Drug Updates
,
FDA Approvals
Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer
Read More
Drug Updates
,
FDA Approvals
Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer
Read More
Drug Updates
,
FDA Approvals
Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection
Read More
Drug Updates
,
FDA Approvals
,
Pancreatic Cancer
Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
Mixed Findings in Annual Cancer Statistics Report
Read More
13
14
15
16
17
18
19
Page 16 of 31
Results 151 - 160 of 305